BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

759 related articles for article (PubMed ID: 11840146)

  • 61. Graft-versus-host reaction spares normal stem cells in chronic myelogenous leukemia.
    Kolb HJ; Mittermüller J; Holler E; Thalmeier K; Bartram CR
    Bone Marrow Transplant; 1996 Mar; 17(3):449-52. PubMed ID: 8704705
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Preemptive treatment of minimal residual disease post transplant in CML using real-time quantitative RT-PCR: a prospective, randomized trial.
    Kim YJ; Kim DW; Lee S; Chung NG; Hwang JY; Kim YL; Min CK; Kim CC
    Bone Marrow Transplant; 2004 Mar; 33(5):535-42. PubMed ID: 14716340
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treatment.
    Scheuring UJ; Pfeifer H; Wassmann B; Brück P; Gehrke B; Petershofen EK; Gschaidmeier H; Hoelzer D; Ottmann OG
    Leukemia; 2003 Sep; 17(9):1700-6. PubMed ID: 12970767
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Influence of graft-versus-host disease on long-term survival of 26 patients with hematologic malignancies after transplantation].
    Lin Q; Dong M; Wang QM; Wen JY; Wu XY
    Ai Zheng; 2006 Oct; 25(10):1261-5. PubMed ID: 17059772
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Allogeneic bone marrow transplantation (BMT) for adults with acute lymphoblastic leukemia (ALL): predictive role of minimal residual disease monitoring on relapse.
    Miglino M; Berisso G; Grasso R; Canepa L; Clavio M; Pierri I; Pietrasanta D; Gatto S; Varaldo R; Ballerini F; Verdiani S; Casarino L; DeStefano F; Sessarego M; Dominietto A; Raiola AM; Bregante S; di Grazia C; Gobbi M; Bacigalupo A
    Bone Marrow Transplant; 2002 Nov; 30(9):579-85. PubMed ID: 12407432
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplantation: prognostic significance of the dose of CD3(+) and CD4(+) lymphocytes.
    Vela-Ojeda J; García-Ruiz Esparza MA; Reyes-Maldonado E; Jiménez-Zamudio L; Moreno-Lafont M; García-Latorre E; Ramírez-Sanjuan E; Montiel-Cervantes L; Tripp-Villanueva F; García-León LD; Ayala-Sánchez M; Rosas-Cabral A; Aviña-Zubieta JA; Galindo-Rodríguez G; Vadillo-Buenfil M; Salazar-Exaire D
    Ann Hematol; 2004 May; 83(5):295-301. PubMed ID: 15060749
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Additional chromosomal abnormalities and variability of BCR breakpoints in Philadelphia chromosome/BCR-ABL-positive acute lymphoblastic leukemia in Taiwan.
    Ko BS; Tang JL; Lee FY; Liu MC; Tsai W; Chen YC; Wang CH; Sheng MC; Lin DT; Lin KH; Tien HF
    Am J Hematol; 2002 Dec; 71(4):291-9. PubMed ID: 12447959
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Allogeneic stem cell transplantation in first complete remission enhances graft-versus-leukemia effect in adults with acute lymphoblastic leukemia: antileukemic activity of chronic graft-versus-host disease.
    Lee S; Cho BS; Kim SY; Choi SM; Lee DG; Eom KS; Kim YJ; Kim HJ; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Shin WS; Kim CC
    Biol Blood Marrow Transplant; 2007 Sep; 13(9):1083-94. PubMed ID: 17697971
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Monitoring of minimal residual disease in patients with chronic myeloleukemia: clinical value of real-time polymerase chain reaction].
    Chelysheva EIu; Turkina AG; Misiurin AV; Aksenova EV; Domracheva EV; Zakharova AV; Khoroshko ND
    Ter Arkh; 2007; 79(4):49-53. PubMed ID: 17564019
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Poor correlation of kinetics between BCR-ABL and WT1 transcript levels after allogeneic stem cell transplantation.
    Uzunel M; Ringdén O
    Bone Marrow Transplant; 2004 Jan; 33(1):47-52. PubMed ID: 14704656
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Minimal residual disease status in transplanted chronic myelogenous leukemia patients: low incidence of polymerase chain reaction positive cases among 48 long disease-free subjects who received unmanipulated allogeneic bone marrow transplants.
    Guerrasio A; Martinelli G; Saglio G; Rosso C; Zaccaria A; Rosti G; Testoni N; Ambrosetti A; Izzi T; Sessarego M
    Leukemia; 1992 Jun; 6(6):507-12. PubMed ID: 1602789
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Allogeneic blood stem cell transplantation in chronic myeloid leukaemia-chronic phase following conditioning with busulphan and cyclophosphamide: a follow up report.
    Saikia TK; Parikh PM; Tawde S; Amare-Kadam PS; Rajadhyaksha S; Chhaya S
    Natl Med J India; 2004; 17(2):71-3. PubMed ID: 15141598
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Lineage involvement by BCR/ABL in Ph+ lymphoblastic leukemias: chronic myelogenous leukemia presenting in lymphoid blast vs Ph+ acute lymphoblastic leukemia.
    Anastasi J; Feng J; Dickstein JI; Le Beau MM; Rubin CM; Larson RA; Rowley JD; Vardiman JW
    Leukemia; 1996 May; 10(5):795-802. PubMed ID: 8656674
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation.
    Bär BM; Schattenberg A; Mensink EJ; Geurts Van Kessel A; Smetsers TF; Knops GH; Linders EH; De Witte T
    J Clin Oncol; 1993 Mar; 11(3):513-9. PubMed ID: 8445426
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Rituximab can be useful as treatment for minimal residual disease in bcr-abl-positive acute lymphoblastic leukemia.
    Jándula BM; Nomdedeu J; Marín P; Vivancos P
    Bone Marrow Transplant; 2001 Jan; 27(2):225-7. PubMed ID: 11281397
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Molecular basis of chronic myelogenous leukemia and significance of diagnostic methods based on BCR-ABL gene amplification].
    Sacha T; Dulak J; Skotnicki AB; Dembińska-Kiec A
    Przegl Lek; 1999; 56 Suppl 1():57-61. PubMed ID: 10494184
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Donor leukocyte infusions to treat hematologic malignancy relapse following allo-SCT in a pediatric population.
    Levine JE; Barrett AJ; Zhang MJ; Arora M; Pulsipher MA; Bunin N; Fort J; Loberiza F; Porter D; Giralt S; Drobyski W; Wang D; Pavletic S; Ringden O; Horowitz MM; Collins R
    Bone Marrow Transplant; 2008 Aug; 42(3):201-5. PubMed ID: 18490913
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Tyrosine kinase inhibitor STI571 in the treatment of Philadelphia chromosome-positive leukaemia failing myeloablative stem cell transplantation.
    Au WY; Lie AK; Ma SK; Wan TS; Liang R; Chan EC; Kwong YL
    Bone Marrow Transplant; 2002 Oct; 30(7):453-7. PubMed ID: 12368958
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The graft-versus-leukemia effect of nonmyeloablative stem cell allografts may not be sufficient to cure chronic myelogenous leukemia.
    Sloand E; Childs RW; Solomon S; Greene A; Young NS; Barrett AJ
    Bone Marrow Transplant; 2003 Nov; 32(9):897-901. PubMed ID: 14561990
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Detection of BCR-ABL gene sequences using RT-PCR in patients with leukemia in the IX region. Chile].
    Artigas CG; Melo A; Roa JC; Páez E; Vittini C; Arriagada M; González L; Pflaumer E; Roa I
    Rev Med Chil; 2002 Jun; 130(6):623-30. PubMed ID: 12194684
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.